Page last updated: 2024-08-21

alpha-aminopyridine and Weight Reduction

alpha-aminopyridine has been researched along with Weight Reduction in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's8 (72.73)24.3611
2020's2 (18.18)2.80

Authors

AuthorsStudies
Chen, YX; Fan, J; Huang, L; Wang, JH1
Ameye, L; Awada, A; Azambuja, E; Brandão, M; Caparica, R; De Angelis, C; Desmedt, C; Di Cosimo, S; Eiger, D; Franzoi, MA; Kotecki, N; Lambertini, M; Piccart, M; Ponde, N1
Arner, EN; Brekken, RA; Cruz, VH; Scherer, PE; Wynne, KW1
Horna, O; Toyas, C1
Janez, A; Jensterle, M; Kocjan, T; Salamun, V; Vrtacnik Bokal, E1
Anderberg, RH; Banke, E; Berqquist, F; Eerola, K; Gribble, FM; Hansson, C; Lamy, CM; López-Ferreras, L; Nissbrandt, H; Reimann, F; Richard, JE; Skibicka, KP; Wernstedt Asterholm, I1
Izquierdo Alonso, JL1
Martínez, FJ1
Bredenbröker, D; Brose, M; Calverley, PMA; Goehring, UM; Martinez, FJ; Rabe, KF; Wedzicha, JA1
Chang, L; Chiang, SH; Decker, SJ; Downes, M; Evans, RM; Hochberg, I; Larsen, MJ; Li, P; Liddle, C; Mowers, J; Oh, D; Olefsky, JM; Reilly, SM; Rubin, JR; Saltiel, AR; Uhm, M; White, NM; Yu, RT1
Hayashi, A; Miyata, K; Sasamata, M; Suzuki, M1

Reviews

2 review(s) available for alpha-aminopyridine and Weight Reduction

ArticleYear
[Clinical profile of roflumilast].
    Archivos de bronconeumologia, 2010, Volume: 46 Suppl 10

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Bronchitis; Bronchodilator Agents; Chronic Disease; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Forced Expiratory Volume; Humans; Mice; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Rats; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome; Weight Loss

2010
[Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
    Archivos de bronconeumologia, 2010, Volume: 46 Suppl 9

    Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Inflammation; Multicenter Studies as Topic; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Treatment Outcome; Weight Loss

2010

Trials

3 trial(s) available for alpha-aminopyridine and Weight Reduction

ArticleYear
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
    Journal of the National Cancer Institute, 2021, 04-06, Volume: 113, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidazoles; Body Mass Index; Breast Neoplasms; Confidence Intervals; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neutropenia; Obesity; Odds Ratio; Overweight; Placebos; Progression-Free Survival; Thinness; Weight Loss

2021
Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
    Journal of ovarian research, 2015, Jun-02, Volume: 8

    Topics: Adult; Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Female; Glucagon-Like Peptide-1 Receptor; Humans; Liraglutide; Metformin; Obesity; Phosphodiesterase 4 Inhibitors; Polycystic Ovary Syndrome; Weight Loss

2015
Efficacy of roflumilast in the COPD frequent exacerbator phenotype.
    Chest, 2013, Volume: 143, Issue:5

    Topics: Aged; Aminopyridines; Benzamides; Cyclopropanes; Diarrhea; Disease Progression; Double-Blind Method; Endpoint Determination; Female; Humans; Incidence; Male; Middle Aged; Phenotype; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Treatment Outcome; Weight Loss

2013

Other Studies

6 other study(ies) available for alpha-aminopyridine and Weight Reduction

ArticleYear
Inhibition of A
    Mediators of inflammation, 2020, Volume: 2020

    Topics: Adenosine A2 Receptor Agonists; Aminopyridines; Animals; Apoptosis; Cell Proliferation; Enterocolitis, Necrotizing; Immunohistochemistry; Interferon-gamma; Interleukin-6; Male; Peroxidase; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2B; Signal Transduction; Tumor Necrosis Factor-alpha; Weight Loss

2020
Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction.
    Molecular metabolism, 2018, Volume: 16

    Topics: Aminopyridines; Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Fatty Liver; I-kappa B Kinase; Insulin; Insulin Resistance; Male; Metabolic Diseases; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Phosphorylation; Protein Serine-Threonine Kinases; Signal Transduction; Weight Loss

2018
[Intractable diarrhoea and severe weight loss by roflumilast].
    Medicina clinica, 2013, Aug-04, Volume: 141, Issue:3

    Topics: Aged; Aminopyridines; Animals; Anorexia; Benzamides; Bronchitis; Comorbidity; Cyclopropanes; Diarrhea; Drug Evaluation, Preclinical; Female; Gastrointestinal Tract; Hallucinations; Hospitalization; Humans; Patient Readmission; Phosphodiesterase Inhibitors; Polypharmacy; Product Surveillance, Postmarketing; Pulmonary Disease, Chronic Obstructive; Sleep Apnea Syndromes; Vomiting; Weight Loss

2013
Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight.
    Diabetes, 2017, Volume: 66, Issue:4

    Topics: Aminopyridines; Animals; Anorexia; Appetite; Body Weight; Dorsal Raphe Nucleus; Exenatide; Feeding Behavior; Fenclonine; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Indoles; Liraglutide; Male; Peptides; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Serotonin; Serotonin Antagonists; Venoms; Weight Loss

2017
An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.
    Nature medicine, 2013, Volume: 19, Issue:3

    Topics: Aminopyridines; Animals; Anti-Allergic Agents; Anti-Obesity Agents; Cell Line; Diet, High-Fat; Energy Metabolism; Enzyme Activation; Fatty Liver; Glucose Metabolism Disorders; I-kappa B Kinase; Insulin Resistance; Intra-Abdominal Fat; Male; Mice; Mice, Inbred C57BL; Mice, Obese; NF-kappa B; Obesity; Oxygen Consumption; Protein Serine-Threonine Kinases; Weight Loss

2013
Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats.
    Psychopharmacology, 2005, Volume: 178, Issue:2-3

    Topics: Administration, Oral; Aminopyridines; Animals; Appetite Depressants; Dose-Response Relationship, Drug; Drug Interactions; Energy Metabolism; Ethylamines; Feeding Behavior; Indazoles; Indoles; Male; Piperazines; Rats; Rats, Wistar; Serotonin 5-HT2 Receptor Agonists; Weight Loss

2005